Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Novo Nordisk launched the product in the United States in January 2026, marking the first time an oral GLP-1 treatment had been cleared specifically for weight management
I will be a long time user and customer of VitaStir
No insurance, though HSA/FSA work (reimbursement not guaranteed)
Possible mild, temporary effects can include injection-site irritation, lightheadedness, or GI upset (depending on the peptide)
Iwata R, Casimir P, Erkol E, Boubakar L, Planque M, Gallego Lpez IM, Ditkowska M, Gaspariunaite V, Beckers S, Remans D, et al
Ipamorelin's defining tolerability feature is selectivity: in its foundational pharmacology it stimulated growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH, and without the appetite stimulation seen with other growth-hormone-releasing peptides avoiding several of their characteristic side effects
US$ 22.16
US$ 28.32
US$ 21.84
